Adel Sidky, MD
Interventional Cardiology · Boynton Beach, FLNPI 1235138082
Payments from drug & device makers
Across 691 payments — averaging $32.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$4K
- Cvrx, Inc.$2K
- AstraZeneca$2K
- Bayer$2K
- Boston Scientific$2K
- Amgen$1K
- plus $10K from 38 others
What the payments were for
- Consulting fees$2,1009%
- Travel & lodging$1,8758%
- Food & beverage$17,96581%
- Education$2401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$2,323
- Barostim Neo System$1,713
- Watchman$1,311
- Repatha$877
- Kerendia$838
- FARXIGA$607
- VERQUVO$578
- XARELTO$353
- AMVUTTRA$244
- LODOCO$231
- BRILINTA$227
- ENROUTE Transcarotid Neuroprotection System$187
- ENROUTE Transcarotid Stent$187
- SYNERGY ABLATION SYSTEM$183
- AMPLATZER AMULET$180
- ESPRIT$146
- Carto 3$145
- Quadra Assura CRT Defibrillator$143
- Evera$132
- JARDIANCE$123
How this compares
$22,180 in reported general payments places this provider in the 65th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 431 | $481,434 |
| JardianceEmpagliflozin | 331 | $378,087 |
| FarxigaDapagliflozin Propanediol | 350 | $309,821 |
| XareltoRivaroxaban | 279 | $298,643 |
| Repatha SureclickEvolocumab | 236 | $203,981 |
| OzempicSemaglutide | 143 | $194,522 |
| MounjaroTirzepatide | 104 | $126,104 |
| EliquisApixaban | 107 | $98,421 |
| TrulicityDulaglutide | 55 | $82,313 |
| VascepaIcosapent Ethyl | 118 | $59,220 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $46,599 |
| VerquvoVericiguat | 29 | $45,657 |
| Nebivolol Hcl | 555 | $34,466 |
| RybelsusSemaglutide | 22 | $31,339 |
| Praluent PenAlirocumab | 34 | $24,950 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $840 | $481,434431 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $609 | $402,440356 claims |
| AstraZenecaFarxiga, Nexium | $1,793 | $313,073362 claims |
| Johnson & JohnsonXarelto | $1,357 | $298,643279 claims |
| Novo NordiskOzempic, Rybelsus | $3,673 | $225,861165 claims |
| Lilly USA, LLCMounjaro, Trulicity | $727 | $208,417159 claims |
| PfizerEliquis | $388 | $98,421107 claims |
| MerckVerquvo | $1,068 | $45,65729 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $379 | $12,56922 claims |
| AbbVieLinzess, Synthroid | $54 | $10,20540 claims |
| Sanofi-aventis U.S. LLCLantus | $52 | $4,48111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Boynton Beach
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
- Pedro Martinez-ClarkMiami$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.